Most companies don’t miss drug patent value because they can’t see the science—they miss it because they can’t see the money.
The period before a patent expires is where deals are won or lost: out-licensing, co-development, portfolio swaps, and “right-…

Drug patent expiry isn’t a calendar event—it’s a portfolio risk model. Here’s how to forecast it by country.
If you manage a pharma portfolio, you already know the uncomfortable truth: “patent expiry” is rarely one date. It’s a moving target shaped by …

Can I Take Lipitor and Pain Relievers Before Bedtime? A Comprehensive Guide Taking medications before bedtime can be a common… https://www.Drugchatter.com/chat/21744/can-i-take-lipitor-and-pain-relievers-before-bedtime/

Generic entry is the moment the market stops forgiving. Prices compress, margins evaporate, and the “brand premium” that once felt permanent becomes a rounding error. Most investors and operators focus on the obvious battleground—compound patents, excl…

Biotech IPOs can look like rocket fuel—until you realize the fuel line is patent risk.
If you’re an investor, operator, or advisor watching a company gear up for a public debut, here’s the uncomfortable truth: patent diligence isn’t a “nice-to-have.” I…

Biosimilar entry windows aren’t just math—they’re strategy. Here are 5 costly modeling mistakes companies keep making.
In biosimilars, the “entry window” is often treated like a spreadsheet problem: plug in the dates, apply the rules, and move on. But …

Most teams don’t lose on science—they lose on timing.
In generic and biosimilar development, the “go/no-go” decision is often framed as a technical question: Can we make it? Can we prove it? Can we hit the right endpoints?
But the real inflection p…

Designing Around the Moat: How Generic Developers Can Think About Secondary Formulation Patents
In generic drug development, the “moat” is rarely just the primary patent. It’s often the secondary layer—formulation tweaks, process changes, stability imp…

Pharma doesn’t just “own” a drug patent—it often extends control over time.
That’s the core tension behind the industry’s playbook for maximizing value from patent term extensions and secondary patents. In a world where blockbuster revenue is measured …